Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

NCT05489237 is registered in ClinicalTrials.gov with IDRX, Inc., a wholly owned subsidiary of GSK, LLC as lead sponsor.

NCT NCT05489237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05489237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)
Lead sponsor
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 3, 2022
Completion date
March 26, 2027
Enrollment
276 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system disease, gastrointestinal diseases, gastrointestinal neoplasms, gastrointestinal stromal tumor (gist), metastatic cancer